In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey

Basit Öğe Kaydı
dc.authoridhızel, kenan/0000-0001-8644-139X
dc.authoridKarabay, Oğuz Oguz/0000-0003-1514-1685
dc.authoridyıldız kaya, sibel/0000-0002-6319-7889
dc.authorwosidhızel, kenan/HHS-0134-2022
dc.authorwosidKarabay, Oğuz Oguz/HHN-5893-2022
dc.authorwosidyıldız kaya, sibel/AAI-9667-2021
dc.contributor.authorYıldırım, Figen Sarıgül
dc.contributor.authorUser, Ülkü
dc.contributor.authorSari, Nagehan Didem
dc.contributor.authorKurtaran, Behice
dc.contributor.authorOnlen, Yusuf
dc.contributor.authorŞenateş, Ebubekir
dc.contributor.authorGündüz, Alper
dc.date.accessioned2023-07-26T11:50:41Z
dc.date.available2023-07-26T11:50:41Z
dc.date.issued2022
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naive patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization's objective of eliminating viral hepatitis.en_US
dc.identifier.doi10.5152/tjg.2022.21834
dc.identifier.endpage978en_US
dc.identifier.issn2148-5607
dc.identifier.issue11en_US
dc.identifier.pmid36415900en_US
dc.identifier.scopus2-s2.0-85142524509en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage971en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2022.21834
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12405
dc.identifier.volume33en_US
dc.identifier.wosWOS:000898674900009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorİnce, Nevin
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectDrug Therapy; Drug Users; Hepatitis C Virusen_US
dc.subjectOpioid Agonist Treatment; Virus-Infection; Genotype Distribution; Natural-History; Hcv; Users; Coinfection; Hiv; Therapy; Seroprevalenceen_US
dc.titleIn a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12405.pdf
Boyut:
1.98 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu